A Locked Nucleic Acid Oligonucleotide Targeting MicroRNA 122 Is Well-Tolerated in Cynomolgus Monkeys
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
MicroRNA 122 (miR-122) is liver specific, fine-tunes lipid metabolism, and is required for hepatitis C virus (HCV) abundance. Miravirsen, an oligonucleotide with locked nucleic acid, binds to miR-122, potently inhibiting its activity. We aimed at determining the safety of the miR-122 antagonism in vivo in 6 to 10 cynomolgus monkeys/group intravenously treated with a range of dose levels twice weekly for 4 weeks. Survival, body weights, clinical signs, and cardiovascular and ophthalmologic parameters were unaffected. Anticipated hypolipidemia due to the inhibition of miR-122 was observed in all treated animals. Only the highest dose level produced distinct transient prolongations of clotting times, slight alternative complement pathway activation, and a reversible increase of hepatic transaminases. Distribution half-life was 10–20 minutes, and accumulation was mainly in the kidney and liver with slow elimination. Microscopic examinations revealed granulated Kupffer cells and lymph node macrophages, cytoplasmic vacuolation in proximal renal tubules, and hepatocytes. The granules were most likely phagolysosomes containing miravirsen. A slightly increased incidence of hepatocyte apoptosis was observed in some monkeys given the highest dose; otherwise, there was no evidence of treatment-related degenerative changes in any organ. In conclusion, the maximal inhibition of miR-122 was associated with limited phenotypic changes, indicating that the clinical assessment of miravirsen as host factor antagonist for treatment of HCV infections is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
Esau, C., Davis, S., Murray, S. F., Yu, X. X., Pandey, S. K., Pear, M., Watts, L., Booten, S. L., Graham, M., McKay, R., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.005 · Cited by 2,082 · cited 3×
“The inhibition of the regulatory role of miR-122 with a complementary oligonucleotide has been demonstrated in vivo (Esau et al., 2006).”
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589 · cited 8×
“The miR-122 antagonist miravirsen is an oligonucleotide containing LNA residues (Elmen et al., 2008a).”
InfluentialSelf-citationHepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia
Sankatsing, R. R., Fouchier, S. W., de Haan, S., Hutten, B. A., de Groot, E., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000176191.64314.07 · Cited by 106 · cited 1×
“The increases in transaminase followed a similar time course as reductions in plasma lipids and might be re-lated to cholesterol lowering (Sankatsing et al., 2005).”
Cited by
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
miR-122 – A key factor and therapeutic target in liver disease
Bandiera, S., Pfeffer, S., Baumert, T. F., & Zeisel, M. B. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.004 · Cited by 629
Development of microRNA therapeutics is coming of age
van Rooij, E., & Kauppinen, S. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201100899 · Cited by 625
“…and pharmacological activity have also been reported in other peripheral tissues, such as heart, lung, spleen and bone marrow (Elme´n et al , 2008a,b; Worm et al , 2009; Obad et al , 2011; Hildebrandt-Eriksen et al , 2012; Hullinger et al , 2012; Ranganathan et al , 2012; Zhang et al , 2012).”
The biological functions of miRNAs: lessons from in vivo studies
Vidigal, J. A., & Ventura, A. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.004 · Cited by 488
Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model
Hinkel, R., Penzkofer, D., Zühlke, S., Fischer, A., Husada, W., Xu, Q.-F., Baloch, E., van Rooij, E., Zeiher, A. M., Kupatt, C., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001904 · Cited by 317
Metadata
- Authors
- Hildebrandt-Eriksen, E. S., Aarup, V., Persson, R., Hansen, H. F., Munk, M. E., & ørum, H.
- Venue
- Nucleic Acid Therapeutics
- Publisher
- SAGE Publications
- Published
- 2012-06
- Volume
- 22
- Issue
- 3
- Pages
- 152-161
- ISSN
- 2159-3337 (ISSN-L)
- 2159-3345
- OpenAlex
- W1939069213
- Cited by
- 96
- References
- 3
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.